Results 211 to 220 of about 282,884 (313)

Pregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim The number of pregnancies among women with cystic fibrosis (wwCF) has steadily increased over the past decade. However, the pharmacokinetics (PK) of elexacaftor–tezacaftor–ivacaftor (ETI) during gestation remains uncharacterized, despite its widespread use in this population.
Paulette Magnas   +16 more
wiley   +1 more source

Effect of esomeprazole on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader, in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this study is to evaluate the effects of multiple doses of esomeprazole, a strong proton pump inhibitor and acid‐reducing agent, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader.
Lana Tran   +7 more
wiley   +1 more source

Selective estrogen receptor modifiers on the antidepressant-like effects of electroconvulsive seizures in adolescent rats. [PDF]

open access: yesTransl Psychiatry
Garau C   +4 more
europepmc   +1 more source

Poly(lactic‐co‐glycolic acid) microsphere loaded dissolving microneedles for sustained and coordinated transdermal delivery of desogestrel and ethinyl estradiol

open access: yesBulletin of the Korean Chemical Society, EarlyView.
PLGA‐based sustained‐release microneedles were developed for the delivery of desogestrel and ethinyl estradiol. The system enabled coordinated release of both drugs, suggesting its potential to improve dosing convenience as a long‐acting contraceptive platform.
Young‐Jin Kim   +5 more
wiley   +1 more source

Lack of endothelial estrogen receptor alpha signaling exacerbates abdominal aortic aneurysm in male mice. [PDF]

open access: yesAm J Physiol Heart Circ Physiol
Sharma N   +5 more
europepmc   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

open access: yesBMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy